University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (afternoon panel discussion)

Abstract

Get full access to this article

View all access options for this article.

References

Food and Drug Administration. Guidance for industry: adaptive design clinical trials for drugs and biologics, 2010, https://www.fda.gov/downloads/drugs/guidances/ucm201790.pdf

Patel

Henry

Quyyumi

et al . Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet 2016; 387: 2412–2421.

Park

Liu

Yee

et al .; I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. N Engl J Med 2016; 375: 11–22.

Rugo

Olopade

DeMichele

et al .; I-SPY 2 Investigators. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 2016; 375: 23–34.

DeMichele

Berry

Zujewski

et al . Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res 2013; 19: 2817–2823.

DeMets

Califf

. A historical perspective on clinical trials innovation and leadership: where have the academics gone? JAMA 2011; 305: 713–714.

Mukherjee

. The emperor of all maladies: a biography of cancer. New York: Scribner, 2010.

Berry

Connor

Lewis

. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015; 313: 1619–1620.

Saville

Berry

. Efficiencies of platform clinical trials: a vision of the future. Clin Trials 2016; 13: 358–366.

10.

Marcus

. For a rare disease, drug trials scramble for patients. Wall Street Journal, 19 April 2015, https://www.wsj.com/articles/for-a-rare-disease-drug-trials-scramble-for-patients-1440013683

11.

Esserman

Woodcock

. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 2011; 306: 2608–2609.

12.

James

Sydes

Mason

et al .; STAMPEDE Investigators. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from STAMPEDE (MRC PR08, CRUK/06/019), a randomized controlled trial. J Clin Oncol 2012; 30(5): 26.

13.

Richman

Adams

Quirke

et al .; FOCUS4 Trial Management Group. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. J Clin Pathol 2016; 69: 35–41.

14.

Berry

. Emerging innovations in clinical trial design. Clin Pharmacol Ther 2016; 99: 82–91.

15.

National Cancer Institute. FDA approval for pertuzumab, https://www.cancer.gov/about-cancer/treatment/drugs/fda-pertuzumab (2013, accessed 6 February 2017).

16.

National Cancer Institute. Lung-MAP: master protocol for squamous cell lung cancer, https://www.cancer.gov/types/lung/research/lung-map (2016, accessed 9 February 2017).

17.

Lieberman

Stroup

McEvoy

et al .; for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223.